Skip to main content
Erschienen in: Molecular Diagnosis & Therapy 2/2003

01.06.2003 | Original Research Article

Hyperekplexia (Startle Disease)

A Novel Mutation (S270T) in the M2 Domain of the GLRA1 Gene and a Molecular Review of the Disorder

verfasst von: Dr Pablo Lapunzina, Juan M. Sánchez, Marta Cabrera, Ana Moreno, Alicia Delicado, Maria L. Torres, Angeles M. Mori, José Quero, Isidora Lopez Pajares

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 2/2003

Einloggen, um Zugang zu erhalten

Abstract

Background: We report on a novel mutation (S270T) in the M2 domain of the GLRA1 (α subunit of the glycine receptor) gene causing autosomal dominant hyperekplexia in a neonate, the mother and maternal uncle. All affected members showed the typical clinical features of the disorder. This novel S270T (T1188A) mutation is located in the boundary of the transmembrane M2 domain of the GLRA1 protein, close to other previously reported mutations. Mutations in this ‘hot spot’ domain of GLRA1 are frequent in autosomal dominant yperekplexia but are not usually seen in the autosomal recessive form of the disease in which both the M1 and the carboxy terminal domains have been implicated.
Methods: Genomic DNA was extracted by standard procedures from peripheral blood leukocytes and exon 6 of the GLRA1 gene was amplified using primers and PCR conditions. A complete sequence analysis of the fragment was performed. DNA sequences were analyzed both by direct observation of the electropherogram and by comparison with the published sequence.
Results: The proband had metabolic acidosis, which was probably related to continuous contractions of somatic muscles and intractable hypertonia. Data seem to show a direct relationship between the mechanism of inheritance of the disorder and the location of the molecular defect. The patients showed almost all the clinical signs of hyperekplexia: exaggerated startle response, muscle hypertonia in response to unexpected tactile and/or auditory stimuli, hyperexcitability, and sudden falls.
Literatur
1.
Zurück zum Zitat Rees MI, Lewis TM, Vafa B, et al. Compound heterozygosity and nonsense mutations in the alpha(1)-subunit of the inhibitory glycine receptor in hyperekplexia. Hum Genet 2001; 109: 267–70PubMedCrossRef Rees MI, Lewis TM, Vafa B, et al. Compound heterozygosity and nonsense mutations in the alpha(1)-subunit of the inhibitory glycine receptor in hyperekplexia. Hum Genet 2001; 109: 267–70PubMedCrossRef
2.
Zurück zum Zitat del Giudice EM, Coppola G, Bellini G, et al. A mutation (V260M) in the middle of the M2 pore-lining domain of the glycine receptor causes hereditary hyperekplexia. Eur J Hum Genet 2001; 9: 873–6PubMedCrossRef del Giudice EM, Coppola G, Bellini G, et al. A mutation (V260M) in the middle of the M2 pore-lining domain of the glycine receptor causes hereditary hyperekplexia. Eur J Hum Genet 2001; 9: 873–6PubMedCrossRef
3.
Zurück zum Zitat Tijssen MA, Voorkamp LM, Padberg GW, et al. Startle responses in hereditary hyperekplexia. Arch Neurol 1997; 54: 388–93PubMedCrossRef Tijssen MA, Voorkamp LM, Padberg GW, et al. Startle responses in hereditary hyperekplexia. Arch Neurol 1997; 54: 388–93PubMedCrossRef
4.
Zurück zum Zitat Shiang R, Ryan G, Zhu YZ, et al. Mutations of the alpha 1 subunit of the the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. Nat Genet 1993; 5: 351–8PubMedCrossRef Shiang R, Ryan G, Zhu YZ, et al. Mutations of the alpha 1 subunit of the the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. Nat Genet 1993; 5: 351–8PubMedCrossRef
5.
Zurück zum Zitat Milani N, Mulhardt C, Weber RG, et al. The human glycine receptor beta subunit gene (GLRB): structure, refined chromosomal localization, and population polymorphism. Genomics 1998; 50: 341–5PubMedCrossRef Milani N, Mulhardt C, Weber RG, et al. The human glycine receptor beta subunit gene (GLRB): structure, refined chromosomal localization, and population polymorphism. Genomics 1998; 50: 341–5PubMedCrossRef
6.
Zurück zum Zitat Rees MI, Lewis TM, Kwok JB, et al. Hyperekplexia associated with compound heterozygote mutations in the beta-subunit of the human inhibitory glycine receptor (GLRB). Hum Mol Genet 2002; 11: 853–60PubMedCrossRef Rees MI, Lewis TM, Kwok JB, et al. Hyperekplexia associated with compound heterozygote mutations in the beta-subunit of the human inhibitory glycine receptor (GLRB). Hum Mol Genet 2002; 11: 853–60PubMedCrossRef
7.
Zurück zum Zitat Rees MI, Andrew M, Jawad S, et al. Evidence for recessive as well as dominant forms of startle disease (hyperekplexia) caused by mutations in the alpha 1 subunit of the inhibitory glycine receptor. Hum Mol Genet 1994; 3: 2175–9PubMedCrossRef Rees MI, Andrew M, Jawad S, et al. Evidence for recessive as well as dominant forms of startle disease (hyperekplexia) caused by mutations in the alpha 1 subunit of the inhibitory glycine receptor. Hum Mol Genet 1994; 3: 2175–9PubMedCrossRef
8.
Zurück zum Zitat Shiang R, Ryan SG, Zhu YZ, et al. Mutational analysis of familial and sporadic hyperekplexia. Ann Neurol 1995; 38: 85–91PubMedCrossRef Shiang R, Ryan SG, Zhu YZ, et al. Mutational analysis of familial and sporadic hyperekplexia. Ann Neurol 1995; 38: 85–91PubMedCrossRef
9.
Zurück zum Zitat Tijssen MA, Vergouwe MN, Van Dijk JG, et al. Major and minor form of hereditary hyperekplexia. Mov Disord 2002; 17: 826–30PubMedCrossRef Tijssen MA, Vergouwe MN, Van Dijk JG, et al. Major and minor form of hereditary hyperekplexia. Mov Disord 2002; 17: 826–30PubMedCrossRef
10.
Zurück zum Zitat Rea R, Tijssen MA, Herd C, et al. Functional characterization of compound heterozygosity for GlyRalphal mutations in the startle disease hyperekplexia. Eur J Neurosci 2002; 16: 186–96PubMedCrossRef Rea R, Tijssen MA, Herd C, et al. Functional characterization of compound heterozygosity for GlyRalphal mutations in the startle disease hyperekplexia. Eur J Neurosci 2002; 16: 186–96PubMedCrossRef
11.
Zurück zum Zitat Humeny A, Bonk T, Becker K, et al. A novel recessive hyperekplexia allele GLRA1 (S231R): genotyping by MALDI-TOF mass spectrometry and functional characterisation as a determinant of cellular glycine receptor trafficking. Eur J Hum Genet 2002; 10: 188–96PubMedCrossRef Humeny A, Bonk T, Becker K, et al. A novel recessive hyperekplexia allele GLRA1 (S231R): genotyping by MALDI-TOF mass spectrometry and functional characterisation as a determinant of cellular glycine receptor trafficking. Eur J Hum Genet 2002; 10: 188–96PubMedCrossRef
12.
Zurück zum Zitat Kwok JB, Raskin S, Morgan G, et al. Mutations in the glycine receptor alphal subunit (GLRA1) gene in hereditary hyperekplexia pedigrees: evidence for non-penetrance of mutation Y279C. J Med Genet 2001; 38: E17PubMedCrossRef Kwok JB, Raskin S, Morgan G, et al. Mutations in the glycine receptor alphal subunit (GLRA1) gene in hereditary hyperekplexia pedigrees: evidence for non-penetrance of mutation Y279C. J Med Genet 2001; 38: E17PubMedCrossRef
13.
Zurück zum Zitat Celesia GG. Disorders of membrane channels or channelopathies. Clin Neurophysiol 2001; 112: 2–18PubMedCrossRef Celesia GG. Disorders of membrane channels or channelopathies. Clin Neurophysiol 2001; 112: 2–18PubMedCrossRef
14.
Zurück zum Zitat Vergouwe MN, Tijssen MA, Peters AC, et al. Hyperekplexia phenotype due to compound heterozygosity for GLRA1 gene mutations. Ann Neurol 1999; 46: 634–8PubMedCrossRef Vergouwe MN, Tijssen MA, Peters AC, et al. Hyperekplexia phenotype due to compound heterozygosity for GLRA1 gene mutations. Ann Neurol 1999; 46: 634–8PubMedCrossRef
15.
Zurück zum Zitat Moorhouse AJ, Jacques P, Barry PH, et al. The startle disease mutation Q266H, in the second transmembrane domain of the human glycine receptor, impairs channel gating. Mol Pharmacol 1999; 55: 386–95PubMed Moorhouse AJ, Jacques P, Barry PH, et al. The startle disease mutation Q266H, in the second transmembrane domain of the human glycine receptor, impairs channel gating. Mol Pharmacol 1999; 55: 386–95PubMed
16.
Zurück zum Zitat Saul B, Kuner T, Sobetzko D, et al. Novel GLRA1 missense mutation (P250T) in dominant hyperekplexia defines an intracellular determinant of glycine receptor channel gating. J Neurosci 1999; 19: 869–77PubMed Saul B, Kuner T, Sobetzko D, et al. Novel GLRA1 missense mutation (P250T) in dominant hyperekplexia defines an intracellular determinant of glycine receptor channel gating. J Neurosci 1999; 19: 869–77PubMed
17.
Zurück zum Zitat Bernasconi A, Regli F, Schorderet DF, et al. Familial hyperekplexia: startle disease: clinical, electrophysiological and genetic study of a family. Rev Neurol (Paris) 1996; 152: 447–50 Bernasconi A, Regli F, Schorderet DF, et al. Familial hyperekplexia: startle disease: clinical, electrophysiological and genetic study of a family. Rev Neurol (Paris) 1996; 152: 447–50
18.
Zurück zum Zitat Elmslie FV, Hutchings SM, Spencer V, et al. Analysis of GLRA1 in hereditary and sporadic hyperekplexia: a novel mutation in a family cosegregating for hyperekplexia and spastic paraparesis. J Med Genet 1996; 33: 435–6PubMedCrossRef Elmslie FV, Hutchings SM, Spencer V, et al. Analysis of GLRA1 in hereditary and sporadic hyperekplexia: a novel mutation in a family cosegregating for hyperekplexia and spastic paraparesis. J Med Genet 1996; 33: 435–6PubMedCrossRef
19.
Zurück zum Zitat Brune W, Weber RG, Saul B, et al. A GLRA1 null mutation in recessive hyperekplexia challenges the functional role of glycine receptors. Am J Hum Genet 1996; 58: 989–97PubMed Brune W, Weber RG, Saul B, et al. A GLRA1 null mutation in recessive hyperekplexia challenges the functional role of glycine receptors. Am J Hum Genet 1996; 58: 989–97PubMed
20.
Zurück zum Zitat Milani N, Dalpra L, del Prete A, et al. A novel mutation (Gln266→His) in the alpha 1 subunit of the inhibitory glycine-receptor gene (GLRA1) in hereditary hyperekplexia. Am J Hum Genet 1996; 58: 420–2PubMed Milani N, Dalpra L, del Prete A, et al. A novel mutation (Gln266→His) in the alpha 1 subunit of the inhibitory glycine-receptor gene (GLRA1) in hereditary hyperekplexia. Am J Hum Genet 1996; 58: 420–2PubMed
21.
Zurück zum Zitat Tijssen MA, Shiang R, van Deutekom J, et al. Molecular genetic reevaluation of the Dutch hyperekplexia family. Arch Neurol 1995; 52: 578–82PubMedCrossRef Tijssen MA, Shiang R, van Deutekom J, et al. Molecular genetic reevaluation of the Dutch hyperekplexia family. Arch Neurol 1995; 52: 578–82PubMedCrossRef
22.
Zurück zum Zitat Rajendra S, Lynch JW, Pierce KD, et al. Mutation of an arginine residue in the human glycine receptor transforms beta-alanine and taurine from agonists into competitive antagonists. Neuron 1995; 14: 169–75PubMedCrossRef Rajendra S, Lynch JW, Pierce KD, et al. Mutation of an arginine residue in the human glycine receptor transforms beta-alanine and taurine from agonists into competitive antagonists. Neuron 1995; 14: 169–75PubMedCrossRef
23.
Zurück zum Zitat Akabas MH, Stauffer DA, Xu M, et al. Acetylcoline receptor channel structure probed in cysteine-substitution mutants. Science 1992; 258: 307–10PubMedCrossRef Akabas MH, Stauffer DA, Xu M, et al. Acetylcoline receptor channel structure probed in cysteine-substitution mutants. Science 1992; 258: 307–10PubMedCrossRef
24.
Zurück zum Zitat Karlin A, Akabas MH. Toward a structural basis for the function of nicotinic acetylcoline receptors and their cousins. Neuron 1995; 15: 1231–44PubMedCrossRef Karlin A, Akabas MH. Toward a structural basis for the function of nicotinic acetylcoline receptors and their cousins. Neuron 1995; 15: 1231–44PubMedCrossRef
25.
26.
Zurück zum Zitat Mokrousov I, Narvskaya O, Otten T, et al. High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother 2002; 46: 1417–24PubMedCrossRef Mokrousov I, Narvskaya O, Otten T, et al. High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother 2002; 46: 1417–24PubMedCrossRef
27.
Zurück zum Zitat Chen CH, Shyu PW, Wu SJ, et al. Identification of a novel point mutation (S65T) in alpha-galactosidase A gene in Chinese patients with Fabry disease: mutations in brief no. 169 [online]. Hum Mutat 1998; 11: 328–30PubMedCrossRef Chen CH, Shyu PW, Wu SJ, et al. Identification of a novel point mutation (S65T) in alpha-galactosidase A gene in Chinese patients with Fabry disease: mutations in brief no. 169 [online]. Hum Mutat 1998; 11: 328–30PubMedCrossRef
28.
Zurück zum Zitat Diamantis ID, McGandy C, Chen TJ, et al. A new mutational hot-spot in the p53 gene in human hepatocellular carcinoma. J Hepatol 1994; 20: 553–6PubMedCrossRef Diamantis ID, McGandy C, Chen TJ, et al. A new mutational hot-spot in the p53 gene in human hepatocellular carcinoma. J Hepatol 1994; 20: 553–6PubMedCrossRef
Metadaten
Titel
Hyperekplexia (Startle Disease)
A Novel Mutation (S270T) in the M2 Domain of the GLRA1 Gene and a Molecular Review of the Disorder
verfasst von
Dr Pablo Lapunzina
Juan M. Sánchez
Marta Cabrera
Ana Moreno
Alicia Delicado
Maria L. Torres
Angeles M. Mori
José Quero
Isidora Lopez Pajares
Publikationsdatum
01.06.2003
Verlag
Springer International Publishing
Erschienen in
Molecular Diagnosis & Therapy / Ausgabe 2/2003
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI
https://doi.org/10.1007/BF03260028

Weitere Artikel der Ausgabe 2/2003

Molecular Diagnosis & Therapy 2/2003 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.